Obesity drug developer Kalohexis files confidentially for U.S. IPO
Seeking Alpha ·
Kalohexis, a clinical-stage biotech developing a series of peptide therapies for conditions including obesity, announced on Tuesday that it has confidentially filed with the Securities and Exchange Commission for a potential U.S. initial public offering, The Northbrook, IL-based biotech, which was launched
DYAX Investor Sentiment
Bullish (Long) 32% · Bearish (Short) 68%
406 participants
Related News
- AI infrastructure: $1.5T CapEx wave and the risks building beneath it
- Democratic leaders question Trump Media & Technology, Kalshi, Polymarket on IRS settlement
- Perplexity says it plans to use Nvidia's new CPU
- Midera Food Processing begins trading after Middleby spin off
- GE Vernova leads power generation equipment stocks lower after Siemens Energy downgrade
- JPMorgan Cuts Yuan Bets Despite 3% Gain, Eyes New Currency Winners